
JPMorgan Chase (NYSE: JPM) passes all three hard screening criteria: ROE of ~17.1% / 18.2% / 19.8% for FY2023–FY2025 (highest in its 8-bank peer group), positive OCF-minus-CapEx FCF of $61.2B / $66.1B / $74.2B, and a trailing P/E of 14.41x — only 5% above the peer median while the ROE lead is 4–9 percentage points. The article covers all nine required information areas: business model (4-segment breakdown: CCB, CIB, AWM, Corporate), ROE table with FY2023 data-source discrepancy disclosed, dual-methodology FCF chart, revenue + earnings growth chart, full 8-bank peer valuation comparison table (P/E, forward P/E, P/B, ROE, dividend yield), bank-appropriate balance sheet analysis using CET1 (13.7% Q1 2026 vs 11.5% minimum), five risk factors (Dimon succession ~$40B 5% impact, $40B+ cumulative regulatory exposure, insider selling pattern, NII rate risk, low short interest), near-term catalysts (Q2 July 14 earnings, 14-year dividend growth streak at $1.50/quarter, $50B buyback, analyst consensus $336–342 target), and competitive moat (scale $4.25T+, 52% vs 61% efficiency ratio vs BAC, #1 IB fees, $17B tech budget). Closes with a structured bull/bear framework anchored on July 14 NII trajectory and 33.6% P/E premium vs. 5-year average.
| Fiscal year | Net income | Common equity (end of year) | ROE |
|---|---|---|---|
| FY2023 (ended Jan 31, 2024) | ~$49.6B (StockAnalysis) | ~$290B | ~17.1% ✓ |
| FY2024 (ended Jan 31, 2025) | $54.3B (SEC EDGAR) | $298.1B | 18.22% ✓ |
| FY2025 (ended Jan 31, 2026) | $60.6B (SEC EDGAR) | $306.0B | 19.79% ✓ |
| TTM (through Mar 31, 2026) | $57.5B | $364.0B | 16.46% ✓ |
| Fiscal year | Revenue | YoY growth | Net income | Operating income |
|---|---|---|---|---|
| FY2021 | $121.6B | — | n/a | — |
| FY2022 | $128.7B | +5.8% | n/a | — |
| FY2023 | $158.1B | +22.8% | ~$49.6B | $50.3B |
| FY2024 | $180.3B | +14.0% | $54.3B | $67.0B |
| FY2025 | $205.1B | +13.8% | $60.6B | $74.2B |
| Q1 2026 (quarter) | $53.2B | — | $16.5B | — |
| Company | Trailing P/E | Forward P/E | P/B | ROE | Div yield |
|---|---|---|---|---|---|
| JPM (JPMorgan Chase) | 14.41x | 13.60x | 2.34x | 16.46% | 1.99% |
| BAC (Bank of America) | 13.02x | 11.52x | 1.36x | 10.64% | 2.14% |
| WFC (Wells Fargo) | 12.15x | 10.87x | 1.48x | 12.03% | 2.29% |
| C (Citigroup) | 16.16x | 11.70x | 1.16x | 7.65% | 1.85% |
| GS (Goldman Sachs) | 19.06x | 17.46x | 2.92x | 14.55% | 1.73% |
| MS (Morgan Stanley) | 19.04x | 17.73x | 3.18x | 16.39% | 1.90% |
| USB (U.S. Bancorp) | 11.14x | 10.27x | 1.40x | 12.35% | 3.91% |
| PNC (PNC Financial) | 12.68x | 11.14x | 1.52x | 12.10% | 3.12% |
| Peer median (7 peers excl. JPM) | 13.72x | 11.61x | 1.50x | 12.10% | 2.14% |
| Metric | Q1 2026 | FY2025 | FY2024 | FY2023 |
|---|---|---|---|---|
| Total assets | $4,217B | $4,159B | $4,020B | $3,874B |
| Common equity (book) | $301.2B | $306.0B | $298.1B | $290.1B |
| Book value per share | $128.38 | — | — | — |
| CET1 ratio (standardized) | 13.7% | 13.8% | 13.5% | 13.2% |
| Regulatory CET1 minimum | 11.5% | — | — | — |
| Excess CET1 above minimum | ~220 bps | — | — | — |
| Total Loss-Absorbing Capacity (TLAC) | $564B | — | — | — |
stockanalysis.com
finance.yahoo.com
macrotrends.net
stockanalysis.com
stockanalysis.com
stockanalysis.com
stockanalysis.com
stockanalysis.com
stockanalysis.com
stockanalysis.com
federalreserve.gov
bankingdive.com
goodjobsfirst.org
This story was produced automatically by a channel. One sentence is all it takes for Neodrop to keep producing for you.
| Stock price | $300.85 |
| Trailing P/E | 14.41x |
| Forward P/E | 13.60x (12.74x Finviz) |
| P/B | 2.34x |
| PEG | 1.52x |
| Enterprise value | $545B |
| Dividend yield | 1.99% |
| 52-week range | $260.31–$337.25 |